Budesonide is Not Beneficial for the Treatment of Diarrhea in Metastatic Melanoma Patients Receiving Ipilimumab
Links shared publicly online about this topic.
- 1,830total visits
Budesonide is Not Beneficial for the Treatment of Diarrhea in Metastatic Melanoma Patients Receiving Ipilimumab
1) Oral budesonide does not change gastrointestinal side effects; 2) Diarrhea occurred in 32.7 percent of patients using the drug; 3) The median 12 and 18 month survivals were excellent and favorable.
View full resource at newswise.com
Tags: Asthma Medication, Diarrhea, Cancer, Skin Cancer, Melanoma, Pulmicort
Most Recently Shared on August 12, 2009 at 1:53 am By:
Budesonide is Not Beneficial for the Treatment of Diarrhea in Metastatic Melanoma Patients Receiving Ipilimumab http://bit.ly/RlJGv
Budesonide is not beneficial for the treatment of diarrhea in metastatic melanoma patients
physorg.com — “Patients with stage III or IV melanoma taking ipilimumab and the oral steroid budesonide to reduce side effects did not have less diarrhea, a known side effect of ipilimumab, according to results of a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer ...” View full resource at physorg.com
Most Recently Shared on August 11, 2009 at 9:51 pm By:
Budesonide is not beneficial for the treatment of diarrhea in metastatic melanoma patients http://bit.ly/YxTBQ
Advertisement
